Navigation Links
Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
Date:6/12/2009

DOYLESTOWN, Pa., June 12 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced the resignation of Guy J. Quigley as Chairman, President and Chief Executive Officer of the Company. The resignation is effective immediately, following a proxy contest which culminated on May 20 at the Company's annual meeting which favored dissident shareholder Ted Karkus and his proposed slate of directors. The Company has accepted the resignation of Charles A. Phillips, COO of The Quigley Corporation and Wendy D. Quigley, Accounting Operations Manager. Mr. Phillips and Ms. Quigley have been with the Company since its inception in 1989.

Guy J. Quigley founded The Quigley Corporation at his dining room table, self funding the company for its first six years without a salary. Mr. Quigley took the Company public in 1991 and established the COLD-EEZE(R) brand in 1992.

Under his leadership, COLD-EEZE has become the number three selling cough cold lozenge and the number one pharmacist recommended zinc cold treatment.

In 2001, he established Quigley Pharma Inc., with a focus on the research and development of naturally-derived compounds. As part of his strategic plan to develop the pharma operation, he oversaw its self-funding with the revenue generated by COLD-EEZE. Under his leadership, $28 million has been self-funded in Quigley Pharma since inception, without any dilution to shareholders.

Since that time, Quigley Pharma has brought two drug development programs to the position where they can begin to offer stockholders value. Findings of significantly improved nerve conduction in patients with Diabetic Peripheral Neuropathy demonstrate that the QR-333 compound has potential to generate value for stockholders. Conversations with four potential veterinary drug development partners regarding the QR-448 antiviral development program are ongoing and demonstrate another source of potential value for stockholders

Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "Despite everything that has been said and done during the course of this proxy contest, my goal has been and continues to build stockholder value. I am very proud of our work over the past 20 years. COLD-EEZE is a highly-respected product and well-established household name and Quigley Pharma has several compounds which have reached a point of value inflection."

"The new Board is now tasked with the responsibility of rewarding stockholders who have patiently held their shares over the years, and refrain from rewarding only those who they bring to the table at the 11th hour to profit from the years of work and patience on behalf of the resigning Board, and the stockholders of The Quigley Corporation. We remain hopeful that the newly elected Board will convert value from the table that has been set for them. To ensure the Company continues to function in the wake of the new Board's unknown plans, I have asked our CFO, Gerard Gleeson to remain in charge until further announcements by the new Board of Directors."

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfilling other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com), which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:        Media                        Investor Relations
                    Karen Pineman                Carl Hymans
                    G.S. Schwartz & Co.          G.S. Schwartz & Co.
                    212.725.4500                 212.725.4500
                    kpineman@schwartz.com        carlh@schwartz.com


'/>"/>
SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division
2. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
3. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
4. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
5. Helix BioPharma Chairman resigns
6. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
7. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
8. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
9. Vasogen Appoints Dr. Eldon Smith Chairman
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... 2016 , ... Shimadzu Scientific Instruments (SSI) will be showcasing ... Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for ... stop by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC ...
(Date:4/27/2016)... Islands (PRWEB) , ... April 27, 2016 , ... ... Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief ... an Executive Director and one of the founding commercial leaders responsible for the ...
(Date:4/27/2016)... ... , ... Global Stem Cells Group and the University of Santiago ... and development initiatives for potential stem cell protocol management for 2016 – 2020. ... began meeting to establish a working agenda and foster initiatives to promote stem cell ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office ... as one of three finalists for the European Inventor Award 2016 in the category ... will be announced at a ceremony in Lisbon on June 9th. , The human ...
Breaking Biology Technology:
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
Breaking Biology News(10 mins):